AKT1 and metabolic dysfunction-associated steatotic liver disease: Seif El-Din et al., found that the probiotic and metformin treatment of early-stage NAFLD can target intestinal microbiome dysregulation and the p-Akt/mTOR/LC-3II pathway to reduce liver damage in NAFLD rats.